Concepedia

Identification of the optimal combination dosing schedule of neoadjuvant ipilimumab plus nivolumab in macroscopic stage III melanoma (OpACIN-neo): a multicentre, phase 2, randomised, controlled trial

Elisa A. Rozeman, Alexander M. Menzies, Alexander C. J. van Akkooi, Chandra Mani Adhikari, Carolien Bierman, Bart A. van de Wiel, Richard A. Scolyer, Oscar Krijgsman, Karolina Sikorska, Hanna Eriksson,

The Lancet Oncology · 2019 · 522 citations · 25 references

DOI

Concepts

References

25

New response evaluation criteria in solid tumours: Revised RECIST guideline (version 1.1)

E. Eisenhauer, P. Therasse, Jan Bogaerts et al. · European Journal of Cancer · 2008 · 29.5K citations

, , +14

Combined Nivolumab and Ipilimumab or Monotherapy in Untreated Melanoma

James Larkin, Vanna Chiarion‐Sileni, René González et al. · New England Journal of Medicine · 2015 · 8.1K citations · Full text

, , +17

Overall Survival with Combined Nivolumab and Ipilimumab in Advanced Melanoma

Jedd D. Wolchok, Vanna Chiarion‐Sileni, René González et al. · New England Journal of Medicine · 2017 · 5.4K citations · Full text

, , +17

IFN-γ–related mRNA profile predicts clinical response to PD-1 blockade

Mark Ayers, Jared Lunceford, Michael Nebozhyn et al. · Journal of Clinical Investigation · 2017 · 3.9K citations · Full text

, , +17

Sequential Treatment Assignment with Balancing for Prognostic Factors in the Controlled Clinical Trial

Stuart Pocock, Richard Simon · Biometrics · 1975 · 2.4K citations

, , +12